Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
NEW YORK, Jan. 12, 2016 - The Nasdaq Stock Market (“Nasdaq”) announced today that, pursuant to Listing Rule 5815(a)(1)(B), KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) will be suspended from Nasdaq effective January 13, 2016.
Trading in the Company’s securities has been halted since December 17, 2015. The trading halt will no longer be in effect upon the suspension of KaloBios from Nasdaq, which would allow the Company’s securities to be eligible for trading in the over-the-counter markets under the symbol “KBIOQ.”
A hearing is scheduled for February 25, 2016, to review the company’s appeal of Nasdaq’s December 18, 2015 delist determination.
For news and additional information about the Company, including whether the Company’s securities will trade on another venue, please review the Company’s public filings or contact the Company directly.
For more information about Nasdaq trade halts, visit www.nasdaqtrader.com. For more information about the Nasdaq delisting process, visit listingcenter.nasdaq.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
